- Home
- YETI vs IBRX Comparison
YETI vs IBRX Comparison
Compare YETI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YETI
- IBRX
- Stock Information
- Founded
- YETI 2006
- IBRX 2014
- Country
- YETI United States
- IBRX United States
- Employees
- YETI N/A
- IBRX N/A
- Industry
- YETI Recreational Games/Products/Toys
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YETI Consumer Discretionary
- IBRX Health Care
- Exchange
- YETI Nasdaq
- IBRX Nasdaq
- Market Cap
- YETI 2.7B
- IBRX 2.3B
- IPO Year
- YETI 2018
- IBRX N/A
- Fundamental
- Price
- YETI $32.68
- IBRX $2.12
- Analyst Decision
- YETI Buy
- IBRX Strong Buy
- Analyst Count
- YETI 13
- IBRX 6
- Target Price
- YETI $38.83
- IBRX $9.83
- AVG Volume (30 Days)
- YETI 1.4M
- IBRX 9.4M
- Earning Date
- YETI 11-06-2025
- IBRX 11-10-2025
- Dividend Yield
- YETI N/A
- IBRX N/A
- EPS Growth
- YETI N/A
- IBRX N/A
- EPS
- YETI 2.10
- IBRX N/A
- Revenue
- YETI $1,822,000,000.00
- IBRX $56,600,000.00
- Revenue This Year
- YETI $3.23
- IBRX $629.94
- Revenue Next Year
- YETI $5.13
- IBRX $109.91
- P/E Ratio
- YETI $15.99
- IBRX N/A
- Revenue Growth
- YETI 3.63
- IBRX 4227.22
- 52 Week Low
- YETI $26.61
- IBRX $1.83
- 52 Week High
- YETI $45.25
- IBRX $5.88
- Technical
- Relative Strength Index (RSI)
- YETI 38.61
- IBRX 33.97
- Support Level
- YETI $34.50
- IBRX $2.30
- Resistance Level
- YETI $36.56
- IBRX $2.67
- Average True Range (ATR)
- YETI 1.01
- IBRX 0.12
- MACD
- YETI -0.16
- IBRX -0.03
- Stochastic Oscillator
- YETI 1.77
- IBRX 1.75
About YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.